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CAESAR Trial Collaborators*U.O. di Chirurgia Vascolare, Policlinico Monteluce, Via Brunamonti, I-06122 Perugia, ItalyObjective. The CAESAR Trial aims to assess the outcome of endovascular repair (EVAR) vs surveillance of small
abdominal aortic aneurysms (AAA) with maximum diameter of 4.1–5.4 cm on computerised tomography (CT) scan.
Design. Patients between 50 and 80 years of age, with small AAA, anatomically suitable for EVAR, are randomly allocated
to early EVAR or surveillance. The primary outcome measure is survival. Secondary endpoints include: Aneurysm-related
deaths (defined as any death caused directly or indirectly by rupture or endovascular/open aneurysm repair), AAA rupture,
peri-operative or late complications, conversion to open repair, complications associated with delayed treatment including
loss of treatment options, AAA growth rates and quality of life. Target recruitment is 740 patients to show that early EVAR
is associated with a 15% survival benefit at 54 months.
Progress. Randomisation started in September 2004. By the end of April 2005, 86 patients had been enrolled by 10 active
European centres. Completion of recruitment is expected for September 2006 and publication of the results in mid 2007.Keywords: Abdominal aortic aneurysm; Small aneurysm; Endovascular repair; Randomised controlled trial; Surveillance.Introduction
The strongest known predictor of rupture and
rupture-related death of abdominal aortic aneurysm
(AAA) is the maximum diameter of the aneurysm.
There is considerable historical evidence that elective
surgical repair improves survival of patients with
large AAA.1,2 In contrast, there is only limited
evidence and much debate on the best management
of risk for patients with small AAA (4.1–5.4 cm).3–8
The rupture rate for aneurysms smaller than 5.5 cm
under surveillance is lower than that of larger
aneurysms. However, recent enthusiasm surrounding
endovascular repair of aortic aneurysm (EVAR) has
increased pressure to extend the indications for repair
to smaller aneurysms, because of reduced major
morbidity and stress response of EVAR compared to
open surgery.ing author. Prof Dr P. Cao, MD, U.O. di Chirurgia
liclinico Monteluce, Via Brunamonti, I-06122 Perugia,
: pcao@unipg.it
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Treatment of AAA is appropriate when cumulative
risk of rupture exceeds risk of repair. For the common
low risk patient with AAA !5.5 cm, the balance of
risks between treatment and no treatment may not be
easy. Two large randomized controlled trials (RCT),
one British and one American (UK Small aneurysm
trial and ADAM trial) have attempted to address
this topic by enrolling over 2000 patients random-
ized to early treatment vs surveillance without
reaching any strong conclusions.3,4 The only
evidence from the results of both RCTs was that
the critical issue for patients with small AAA is to
define ‘when’ and not ‘if’ to treat. The risks to be
balanced are those of early treatment with respect
to those of delayed treatment. Because the natural
history of an aneurysm is that of continued
expansion, it was inevitable that about 70% of
patients with small AAA in the surveillance group
required treatment during the 5-year study period,
at a similar rate in both RCTs.
Both RCTs concluded that surveillance was rela-
tively safe and delayed treatment yielded similar
5-year survival rates oft about 66%. However, it also
might be noted thatEur J Vasc Endovasc Surg 30, 245–251 (2005)
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combination of clinical follow up, careful
medical management and strict ultrasound
surveillance, which might be difficult to
achieve in the common practice outside RCT,
– even with a high rate of intervention in a
patient population willing to undergo fre-
quent and reliable surveillance, the rupture
rate of small aneurysm may still be greater
than 2% per year in some subgroups of the
patient population (e.g. females),
– long-term results of one of the two studies
(the UK trial) might indicate a benefit of early
treatment as 8-year mortality in the early
surgery group was 7.2% points lower than
that in the surveillance group. Patients with
long life expectancy benefit the most from
early surgery.9
An additional point of concern is the applica-
bility rate of EVAR, which might be reduced in
patients under surveillance whose AAA is grow-
ing. There is increasing knowledge both from
registries and from large single centre series
showing that both feasibility and long-term out-
comes of EVAR appear to be much worse for larger
aneurysms. Two years after EVAR in the Cleveland
Clinic series, 6.1% of patients with AAA that
measured 5.5 cm or larger had aneurysm-related
deaths and 8.2% required conversion to open
repair, compared to 1.5 and 1.4% respectively, of
those with aneurysms measuring less than 5.5 cm.
Similarly, the 4-year post-operative rupture rate in
the EUROSTAR registry was 10% for AAA
measuring 6.5 cm or more in diameter compared
to 2% for smaller aneurysms.10,11
In the ‘real word’ this uncertainty among optimal
strategies for treatment of small AAA translates in a
high rate of surgical treatment based on arbitrary
indication and personal opinion. Data from large
registries and multicenter experiences on AAA show
that worldwide AAA repair (either endovascular or
open) is performed on aneurysms with a diameter
range from !4 to over 10 cm with variable results.
Forty-five percent of the EUROSTAR patients and
nearly 60% of the Cleveland patients who were treated
with endovascular repair had aneurysms smaller than
5.5 cm.10,11
Therefore, we conclude that endovascular repair
may represent the treatment of choice for small AAAs.
To test this hypothesis, a randomized trial of early
endovascular repair vs surveillance is being
conducted.Eur J Vasc Endovasc Surg Vol 30, September 2005Materials and Methods
The Comparison of surveillance vs Aortic Endograft-
ing for Small Aneurysms Repair study (CAESAR) is a
multicentre randomised trial designed to compare
EVAR vs surveillance with ultrasonography and
computed tomography (CT) in the treatment of aortic
aneurysms between 4 and 5.5 cm in diameter.Purpose and objectives of the CAESAR study
The study includes patients with small AAA (diameter
4.1–5.4 cm defined by computed tomographic scan)
suitable for EVAR. The purpose is to compare
endovascular repair vs surveillance and, eventually
delayed treatment, with respect to patient survival,
AAA rupture and AAA-related death risks.
The primary study endpoint is mortality from any
cause.
Secondary endpoints include: Aneurysm-related
deaths (defined as any death caused directly or
indirectly by rupture or endovascular/open aneurysm
repair), AAA rupture, peri-operative or late compli-
cations, conversion to open repair, complications
associated with delayed treatment including loss of
treatment options, AAA growth rates and health
related quality of life.
All complications are combined in one comprehen-
sive outcome. Complications are assessed at 30 days
(peri-operative) and during the entire length of follow-
up and defined according to the SVS/AAVS reporting
standards.12 A secondary cost analysis will be
performed according to: Cost of the graft, operating
time, length of hospital stay including intensive care
admission, follow-up visits with imaging examin-
ations, need and number of reinterventions, and
blood transfusion.Participants
Entry criteria
All standard-risk patients with an AAA eligible for
EVAR can be considered for participation in the
CAESAR trial. Required entry criteria are shown in
Table 1.
Centre selection
Centres compliant with endovascular/open aortic
repair and who have experience beyond the learning
curve for endovascular AAA repair are accepted in the
trial. This means that, to participate in the trial, each
centre is required to have performed at least 50 AAA
endovascular procedures, have a minimum annual
Table 1. Entry criteria for CAESAR study
Inclusion criteria
Patients of 50–80 years of age
Non symptomatic infrarenal AAA of 4.1–5.4 cm in diameter measured by CT performed within 3 months before randomization
Adequate infrarenal aortic neck (lengthR15 mm diameter%30 mm) and other anatomical configurations suitable for EVAR
Patients have a life expectancy of at least 5 years
Signed informed consent
Exclusion criteria
Ruptured or symptomatic AAA
AAA maximum diameterR5.5 cm
Suprarenal or thoracic aorta aneurysm of more than 4.0 cm
Patient unsuitable for administration of contrast agent
Severe heart, lung, liver or renal disease (serum creatinineR3 mg/dl)
Need for adjunctive major surgical or vascular procedures within 1 month
High likelihood of non compliance with follow-up requirements
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must have provided a track record of all the
endovascular/open AAA procedures performed
during the last 2 years.
Furthermore, the participants in each centre must
agree to submit all eligible patients to randomisation,
to adhere to the guidelines of the trial until it is
concluded, to guarantee strict adherence to follow-up
and to ensure high-quality CT scan and ultrasono-
graphy studies.
Centres must have obtained Human Ethics Com-
mittee approval from their institutions for the conduct
of the randomised trial prior to enrolling patients.Imaging
The criterion for entry into both arms is an aneurysm
diameter measuring 4.1–5.4 cm on CT scan. Because
reproducibility differences between duplex ultra-
sound and CT scanners can lead to significant
variation in AAA diameter, CT measurements are
mandatory to determine the diameter of the aneurysm
and the suitability for EVAR before randomisation. CT
examinations are performed with contrast agent and
slice reconstruction at no more than 5 mm intervals.
The diameter of the aneurysm is defined on CT scan
as the maximum external cross-sectional measurement
in any plane but perpendicular to the vessel axis.
Measurements are reviewed centrally. The core
laboratory for analysis of the imaging data is the
Vascular Surgery Unit, Azienda Ospedaliera, Univer-
sity of Perugia, Italy.Randomisation and management
A patient who meets the entry criteria and is willing to
participate in the study is included after signing the
informed consent form.
All anonymised records of patients with AAA
between 4 and 5.5 cm in diameter not included in thetrial are kept in a separate database. It is of particular
importance that patients found to be unsuitable for the
Caesar study are recorded. Reasons for exclusion are
recorded in order to determine what proportion of
AAA patients are anatomically suitable for EVAR.Randomisation
Randomization was designed with equal probability
of assignment to either of the two groups by means of
a computer-generated random-number list. After
eligibility is verified and the patient is considered
suitable for the study, assignment is made using a
computerized randomization table accessible via the
internet to authorized investigators at each centre
(www.caesarstudy.com). The treatment allocated is
available immediately to the trial investigator, surgeon
and patient. Since many variables are likely to be
specific to each participating centre (i.e. team experi-
ence, case load, etc.), randomisation is stratified by
centre.Treatment groups and follow-upEndovascular repair
For patients randomized to early endovascular treat-
ment, the repair has to be carried out as soon as
possible. Specific procedural details are left to the
discretion of the surgeon.
Before discharge, a color duplex ultrasound and
abdominal plain X-ray (double projection) are
required. Clinical and imaging follow-up are then
performed at 30 days and every 6 months thereafter.
Double projection plain abdominal X-rays are also
used to follow patients after EVAR to assess stent
integrity. CT scan with slice reconstruction at 5 mm
intervals or less is performed annually.
All adverse events occurring after randomisation,
before or after treatment, (e.g. graft migration,
disconnection, persisting endoleak, aneurysm growth,Eur J Vasc Endovasc Surg Vol 30, September 2005
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documented, treated if necessary and recorded.
Surveillance group
Patients who are assigned to the surveillance arm of
the trial are seen every 6 months throughout the study.
Follow-up assessment includes clinical, ultrasonogra-
phy evaluations and annual CT scan. In patients under
surveillance and with creatinine levels of 2 mg/100 ml
or more, the use of contrast agent is not mandatory
and left to the discretion of the investigator.
Ultrasonography is not used to define aneurysm
baseline diameter but only to monitor aneurysm size
and to assess achievement of threshold criteria, that
will need CT scan confirmation.
Surveillance visits continue until either the patient
dies, the trial ends, or surgery is considered and
performed. Surgery is considered only when the
aneurysm grows to 5.5 cm, rapidly increases in
diameter (O1 cm/year), or becomes symptomatic.
Patients in the surveillance group who meet one or
more threshold criteria to be converted to surgical
repair will be evaluated to assess the persistence of
anatomical suitability for EVAR.
Any patient in the surveillance group who requires
repair during follow-up is followed until completion
of the trial. Fig. 1 shows the protocol for enrolled
patients.
Health related quality of life is assessed in both
groups at 6-month intervals with short-form 36-items
(SF-36) questionnaire administration.13
Device
The CAESAR study has been funded to use a single
device in the trial: The Zenithw AAA Endovascular
Graft (William Cook Europe, Bjaeverskov, Denmark).
This also guarantees homogeneity of the results for all
EVAR patients included in the study. Any configur-
ation is allowed, including tube, bifurcated and mono-
iliac devices. Use of ancillary components such as
extensions is left to the discretion of the investigator
performing the procedure. A grant from William Cook
Europe, Bjaeverskov, Denmark will support the
expenses for the organization of the study. However,
the design and the study itself are conducted
independently.Study population and sample size
Required sample size was estimated at 740 patients (i.
e. 370 patients per group) to detect a difference in
survival rates between the EVAR and control group by
the log-rank test with conventional 0.80 power and 5%Eur J Vasc Endovasc Surg Vol 30, September 2005significance.14 The intention is to demonstrate that
mortality rate after 54 months of patients with small
AAA treated early by EVAR is 15% lower than that of
patients in the surveillance group. Survival rates at 12,
36 and 54 months for the surveillance group were
assumed to be 0.98, 0.83 and 0.68% as reported in The
United Kingdom Small Aneurysm Trial Participants.3
The corresponding figures for the EVAR group used
for sample calculation were 0.98, 0.88, and 0.83% at 12,
36 years and 54 months follow-up, respectively, and
were obtained from cases (small AAAs undergone
endovascular treatment) treated at the coordinating
centre. Sample size was calculated taking into account
that risk difference was not constant during follow-up,
thus, the hazard ratio was assumed to be about 1, 0.7
and 0.6 at 12, 36 and 54 months follow-up, respectively.
For sample size calculations we made additional
assumptions: A uniform rate of recruitment over a
2-year period, an additional follow-up at 3 years, and
the proportion lost to follow-up to be as low at 3%.Statistical analysis
The outcome analyses are conducted according to the
intention-to-treat principle. STATA Statistical package
will be used for analyses (Stata Corp. Stata Statistical
Software, release 8.0. College Station, TX: Stata
Corporation, 2003) and performed by the Study
Statistician.
Cumulative survival curves will be used and
the differences between the treatment groups will
be evaluated by log-rank test. Estimates of risk in
the surveillance group compared to the EVAR
group and 95% confidence intervals are calculated
with the use of the Cox proportional hazards
model or parametric models. The survival model
is adjusted for potential confounding variables,
which are expected to influence mortality. These
include age, gender, history of ischemic heart
disease, chronic obstructive airways disease.
Absolute risk, relative risk and number need to
treat (NNT) are calculated as estimates of risk.
P values are two-tailed and are obtained with the
chi-square tests or t-test.Current status
Recruitment began in September 2004, and by the end
of April 2005 a total of 86 patients had been included in
the CAESAR trial by 10 active randomising centres.
Other European Centres recently received Local
Ethical Committee approval to actively randomise.
The CAESAR Data Monitoring Committee has
Fig. 1. Flow chart for patients enrolled into CAESAR Trial.
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completed by the end of August 2006. In order to
accrue sufficient patient years of follow-up, a mini-
mum of 1 year of follow-up is required per patient and
on this timescale we might expect to publish the
results of the trial in mid 2007. However, a final
publication date has not been decided and further
long-term follow-up after EVAR might still be
required before a formal analysis is performed.Conclusions
In this era of endovascular expansion, stent grafting
for small AAA has been reported in several non-
randomised trials with promising results.7,8,10,11,15
Similarly, there are supporting data that surveillanceand delayed treatment could be a safe choice for
patients with small AAA. However, these results were
based on open surgical treatment with a higher peri-
operative mortality rate than endografting.7,16 The
high re-intervention rate reported after endografting
can make the cost effectiveness of this procedure
unfavourable in patients with long life expectancy. On
the other hand, patients with small aneurysms usually
have a more favourable anatomy and the operation
may be more durable lowering the need of reinterven-
tion. These aspects will be clarified by this study.
The CAESAR trial has been launched to answer the
question ‘Can early endovascular repair decrease the
risk of death in patients with abdominal aortic
aneurysm between 4 and 5.5 cm in diameter?’ The
trial will attempt to provide scientific evidence on the
merits of endovascular repair of small AAAs. PatientEur J Vasc Endovasc Surg Vol 30, September 2005
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will be monitored. The normal practice of collaborat-
ing vascular specialists is studied, and appropriate
follow-up schedule will be given to all trial patients.Appendix A. Study Organization
No sponsor supports the design and plan of the study
that was implemented by the Vascular Surgery Center
in Perugia, the Coordinating Centre of the trial. This is
the ‘working’ group of the study and is concerned
principally with day-to day-operations. This group
meets as often as necessary to deal with the wide range
of problems relating to the study, e.g. eligibility,
measurements criteria, adherence to the protocol,
outcome events.
The Coordinating Centre meets periodically with
other participating investigators and organizes peri-
odic workshops to keep the participating centres
actively involved and fully informed about the
ongoing status of the study. This should avoid low
patients accrual, high cross-over rates and incomplete
follow-up. Regular visits by monitoring staff are
planned in each center to assess the regularity of the
study and to ensure uniformity of measurements, data
collection and coding procedures. The Coordinating
Centre also is responsible for the core-lab CT scan
reassessment of patients enrolled in the study.
The Steering Committee, which includes a vascular
specialist committee, is the policy- and decision-
making body of the study and has the final responsi-
bility for the conduct and the reporting of the trial. The
Steering Committee receives regular reports from the
Coordinating Centre concerning all information on the
ongoing study (recruitment rate, adherence to proto-
col, cross-over, etc).
The Monitoring Committee ensures the proper
conduct of the trial, assesses the ethical aspects and
monitors the safety of the trial based on the reports of the
Steering Committee. The Monitoring Committee will be
responsible for reviewing the interim analysis and, if
necessary, implementing the study stopping rule.
AnAdverseEventsCommitteewill conveneasneeded
to adjudicate whether or not serious adverse events are
related to the use of the device and/or the procedure.Appendix B. Participants of the CAESAR Study†
Piergiorgio Cao, MD (Principal Investigator),† Listed in the number of enclosed patients or the timing of adhesion
order.
Eur J Vasc Endovasc Surg Vol 30, September 2005Department of Vascular Surgery, Policlinico Monteluce,
Perugia, Italy; Enrico Vecchiati, MD, Dipartimento di
Chirurgia Vascolare Azienda Ospedaliera S.M. Nuova
Reggio Emilia, Italy; Francesco Mascoli, MD, Diparti-
mento di Chirurgia Vascolare, Ospefdale S. Anna,
Ferrara, Italy; Roberto Troiani, MD, Unita` di Chirurgia
Vascolare, Azienda Ospedaliera di Carrara, Carrara,
Italy; Vicente Riambau, MD, Institute of Cardiovascular
Diseases, Hospital clinic, University of Barcelona,
Barcelona, Spain; Malgorzata Szostek, MD, Klinika
Chirurgii Ogolnej i Chorob Klatki Piersiowej Warszawa,
Poland; Jan Brunkwall, MD, Department of Vascular
Surgery, Koeln Universitaet, Koeln, Germany; Dierk
Scheinert, MD, Herz Zentrum, Universitaet Leipzig,
Leipzig, Germany; Giovanni Torsello, MD, Klinik fu¨r
Gefaesschirurgie, St Franziskus Hospital, Muenster,
Germany; Marek Maruszynski, MD, II Klinika Chirurgii
Ogolnej, Onkologicznej i Naczyniowej Wojskowy Insty-
tut Medyczny, Warszawa, Poland; Volker Ruppert, MD,
Department of Vascular Surgery, Ludwig Maximilians
University, Munchen, Germany; Stefano Michelagnoli,
MD, U.O. Chirurgia Vascolare, Nuovo Ospedale S.
Giovanni di Dio, Firenze, Italy; Jacek Szmidt, MD,
Naczyniowej I Transplantacyjnej Akademii Medycznej,
Warsawa, Poland; Carlo Pratesi, MD, Department of
Vascular Surgery, Universita` degli Studi di Firenze, Italy.Appendix C. Data Monitoring Committee
Peter Bell, Chairman, Leicester, UK; Hajo von Bockel
Leiden, The Netherlands; Paolo Fiorani, Rome, Italy,
Krassi Ivancev, Malmo¨, Sweden.Appendix D. Steering Committee
Piergiorgio Cao (Principal Investigator), Perugia, Italy;
Fabio Verzini, Perugia, Italy; Paola De Rango, Perugia,
Italy; Carlo Setacci, Siena, Italy; Vincent Riambau,
Barcelona, Spain; Jan Brunkwall, Koeln, Germany.Appendix E. Adverse Events Committee
Gianbattista Parlani, Perugia, Italy; Giovanni Torsello,
Mu¨nster, Germany.Note added in proof
Recent insights from randomised studies in EVAR vs
Open Repair, the EVAR 1 Trial including subjects with
Comparison of surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR) Trial 251AAA larger than 5.5 cm and the DREAM Trial for
AAAO 5 cm, seem to support our hypothesis17,18.
EVAR 1 Trial showed in fact an anatomic suitability
rate of 54% in potential candidates for enrolment, with
a wide variety among different centers. Mid-term
results highlighted a significant reduction in AAA-
related death rate after EVAR compared to OR,
starting from a 4% immediate postoperative advan-
tage that persisted during follow-up (aneurysm-
related death estimates at 4 years: 4% vs 7%. This
advantage was not present in the EVAR 2 trial, which
included patients unfit for open repair and random-
ised either in early EVAR or surveillance, suggesting
that older patients with multiple comorbidities and at
high operative risk are not going to benefit from
intervention19. Therefore an early endovascular inter-
vention, at a stage when the AAA is smaller, might suit
a wider patient population with lower operative risk
and hopefully better results.References
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